This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (36)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic

Thanh G. Phan, FRACP; Merian Koh, MB, BS; Eelco F. M. Wijdicks, MD

Arch Neurol. 2000;57:1710-1713.

Background  Limited data are available to guide the management of anticoagulation in patients with intracranial hemorrhage (ICH) at high thromboembolic risk.

Objective  To review the management of anticoagulation in patients with ICH at high thromboembolic risk.

Patients and Methods  We reviewed the management of anticoagulation in 141 patients who have a high risk of ischemic stroke and have ICH while taking warfarin. The 30-day risk of ischemic stroke while not taking anticoagulation treatment was determined using Kaplan-Meier survival estimates.

Results  The indications for anticoagulation were a prosthetic heart valve (52 patients [group 1]), atrial fibrillation and cardioembolic stroke (53 patients [group 2]), and a recurrent transient ischemic attack or an ischemic stroke (36 patients [group 3]). A prior ischemic stroke occurred in 14 (27%) of group 1 patients and in 23 (43%) of group 2 patients. Death occurred in 43% of the 141 patients. The median time not taking warfarin in this cohort was 10 days. Three patients had an ischemic stroke within 30 days of warfarin therapy discontinuation. Using Kaplan-Meier survival estimates, the probability of having an ischemic stroke at 30 days following warfarin therapy cessation in groups 1, 2, and 3 was 2.9% (95% confidence interval, 0%-8.0%), 2.6% (95% confidence interval, 0%-7.6%), and 4.8% (95% confidence interval, 0%-13.6%), respectively. In the 35 patients who had warfarin therapy restarted, none had recurrence of ICH during the same hospitalization.

Conclusions  Discontinuation of warfarin therapy for 1 to 2 weeks has a comparatively low probability of embolic events in patients at high embolic risk. This should be taken into consideration when deciding whether to continue or discontinue anticoagulation in these patients at high embolic risk. Early recurrence of ICH is exceedingly uncommon.

From the Department of Neurology, Mayo Clinic and Foundation, Rochester, Minn.

RELATED ARTICLES

The Dilemma of Reinstituting Anticoagulation for Patients With Cardioembolic Sources and Intracranial Hemorrhage: How Wide Is the Strait Between Skylla and Karybdis?
Werner Hacke
Arch Neurol. 2000;57(12):1682-1684.
EXTRACT | FULL TEXT  

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(12):1794-1795.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage
Claassen et al.
Arch Neurol 2008;65:1313-1318.
ABSTRACT | FULL TEXT  

REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Circulation 2007;116:e391-e413.
ABSTRACT | FULL TEXT  

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Broderick et al.
Stroke 2007;38:2001-2023.
ABSTRACT | FULL TEXT  

Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Circulation 2006;113:e409-e449.
ABSTRACT | FULL TEXT  

Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Sacco et al.
Stroke 2006;37:577-617.
ABSTRACT | FULL TEXT  

Primum non nocere: Antithombotics after intracerebral hemorrhage?
Goldstein
Neurology 2006;66:162-163.
FULL TEXT  

Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions
Steiner et al.
Stroke 2006;37:256-262.
ABSTRACT | FULL TEXT  

Warfarin reversal
Hanley
J. Clin. Pathol. 2004;57:1132-1139.
ABSTRACT | FULL TEXT  

Resolved: Heparin May Be Useful in Selected Patients With Brain Ischemia
Caplan
Stroke 2003;34:230-231.
FULL TEXT  

Management of intracranial bleeding associated with anticoagulation: balancing the risk of further bleeding against thromboembolism from prosthetic heart valves
PHAN et al.
J. Neurol. Neurosurg. Psychiatry 2001;70:820-821.
FULL TEXT  

Intracranial Hemorrhage in Anticoagulated Patients
JWatch General 2001;2001:1-1.
FULL TEXT  

The Dilemma of Reinstituting Anticoagulation for Patients With Cardioembolic Sources and Intracranial Hemorrhage: How Wide Is the Strait Between Skylla and Karybdis?
Hacke
Arch Neurol 2000;57:1682-1684.
FULL TEXT